Form 4: Edgewise Therapeutics Director Peter A. Thompson Reports Significant Stock Purchases

Director Peter A. Thompson reports purchases of Edgewise Therapeutics (EWTX) common stock through indirect holdings via OrbiMed funds.

Summary

• On April 3, 2025, Peter A. Thompson, a director of Edgewise Therapeutics, reported the acquisition of common stock through indirect holdings.
• 372,578 shares were purchased at $20.13 per share through OrbiMed Private Investments VI, LP, resulting in a total holding of 14,809,075 shares.
• An additional 124,193 shares were purchased at $20.13 per share through OrbiMed Genesis Master Fund, L.P., resulting in a total holding of 443,792 shares.
• The purchases were made in connection with an underwritten public offering.
• Thompson disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock purchases. The director's purchase could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• Director's purchase may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders such as directors and officers trade in their company's stock. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Comparing the size of these purchases to similar transactions by directors in comparable biotech companies would provide a better understanding of the significance of this activity.
• For example, directors at companies like Sarepta Therapeutics or BioMarin Pharmaceutical often make similar filings, and analyzing the market reaction to those filings could offer context.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Peter A. Thompson, OrbiMed, stock purchase, Form 4, director, beneficial ownership, public offering